Bees are essential to our ecosystems, food production and biodiversity. But like all animals, they can face health challenges. In the latest episode of Inside EMA, we speak with Miguel Llorens, Scientific Officer in EMA's Veterinary Medicines Division, about the diseases affecting bees, the medicines used to treat them, and how regulators help ensure those medicines are safe, effective and of high quality.

Bees are essential to our ecosystems, food production and biodiversity. But like all animals, they can face health challenges. In the latest episode of Inside EMA, we speak with Miguel Llorens, Scientific Officer in EMA's Veterinary Medicines Division, about the diseases affecting bees, the medicines used to treat them, and how regulators help ensure those medicines are safe, effective and of high quality.

What’s the buzz about bees?

How does EMA help turn innovative ideas into real medicines?In this episode of Inside EMA, we look at how the European Medicines Agency supports developers from early concepts through to patient access. The discussion highlights how regulation and innovation are not opposites, but complementary forces that help deliver safe and effective medicines.Topics include early scientific dialogue, support for SMEs, and EMA’s engagement with innovation ecosystems across Europe.🎙️ Featuring Emmanuel Cormier, Head of regulatoryscience and innovation, and Alessandro Faia, Communications officer.Learn more: <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development#opportunities-to-interact-with-ema-during-the-development-of-a-medicine-38736">Opportunities to interact with EMA during the development of a medicine</a>

How does EMA help turn innovative ideas into real medicines? In this episode of Inside EMA, we look at how the European Medicines Agency supports developers from early concepts through to patient access. The discussion highlights how regulation and innovation are not opposites, but complementary forces that help deliver safe and effective medicines. Topics include early scientific dialogue, support for SMEs, and EMA’s engagement with innovation ecosystems across Europe. 🎙️ Featuring Emmanuel Cormier, Head of regulatoryscience and innovation, and Alessandro Faia, Communications officer. Learn more: Opportunities to interact with EMA during the development of a medicine

How does EMA help turn innovative ideas into real medicines?In this episode of Inside EMA, we look at how the European Medicines Agency supports developers from early concepts through to patient access. The discussion highlights how regulation and innovation are not opposites, but complementary forces that help deliver safe and effective medicines.Topics include early scientific dialogue, support for SMEs, and EMA’s engagement with innovation ecosystems across Europe.🎙️ Featuring Emmanuel Cormier, Head of regulatoryscience and innovation, and Alessandro Faia, Communications officer.Learn more: <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development#opportunities-to-interact-with-ema-during-the-development-of-a-medicine-38736" rel="noopener noreferrer">Opportunities to interact with EMA during the development of a medicine</a>

From idea to medicines: how EMA supports innovation

Obesity rates continue to rise across Europe, but the reasons go far beyond diet and exercise. In this episode, we explore obesity as a chronic disease and look at how weight‑loss medicines like GLP‑1 receptor agonists are influencing treatment and expectations. EMA expert Bart van der Schueren joins us to discuss the biological, behavioural and societal factors that influence weight, and what it means to try to lose weight today.

Obesity rates continue to rise across Europe, but the reasons go far beyond diet and exercise. In this episode, we explore obesity as a chronic disease and look at how weight‑loss medicines like GLP‑1 receptor agonists are influencing treatment and expectations. EMA expert Bart van der Schueren joins us to discuss the biological, behavioural and societal factors that influence weight, and what it means to try to lose weight today.

Beyond the scale, obesity in the age of GLP-1s

To mark European Antibiotic Awareness Day, our first episode dives into one of the biggest global health challenges: antimicrobial resistance (AMR). EMA’s Chief Medical Officer, Steffen Thirstrup, and Communications Officer, Alessandro Faia, explore what drives AMR, its impact in Europe and worldwide, and how EMA is working to enable solutions.Discover why “the drugs don’t work” and what’s being done to protect public health.

To mark European Antibiotic Awareness Day, our first episode dives into one of the biggest global health challenges: antimicrobial resistance (AMR). EMA’s Chief Medical Officer, Steffen Thirstrup, and Communications Officer, Alessandro Faia, explore what drives AMR, its impact in Europe and worldwide, and how EMA is working to enable solutions. Discover why “the drugs don’t work” and what’s being done to protect public health.

The drugs don’t work: Addressing antimicrobial resistance

The official podcast of the European Medicines Agency. This series takes you behind the scenes of medicines regulation in the EU, exploring the science and the experts working to ensure medicines for humans and animals are safe, effective, and of high quality.

Share Inside EMA

Sign up to save your podcasts

Inside EMA

Inside EMA episodes

About Inside EMA